Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...

AI Agents in Clinical Trials require human review before data commits to clinical databases, balancing automation with regulatory accountability.

Intellia secures $400M credit facility to fund the NTLA-2002 HAE trial through completion, avoiding shareholder dilution from equity offerings.

Tarsus Pharmaceuticals acquires gildeuretinol for Stargardt disease, an oral drug in Phase 3 development with FDA breakthrough therapy designation.

Inhibrx releases Phase 2 primary endpoint data for INBRX-106 in head and neck cancer, testing hexavalent OX40 agonist plus...

Pelacarsen fails to meet primary endpoint in Phase 3 Lp(a) trial, raising questions about biomarker-outcome relationships in cardiovascular drug...

A single 600 mg dose of Kylo-11 cut lipoprotein(a) by 97% at 48 weeks in a Phase 1 trial,...

CluePoints launches AI tools for clinical data review with capabilities targeting 99% accuracy in medical coding and cutting manual...

Thryv Therapeutics licenses SGK1 inhibitors from Spanish research institutions for Parkinson's and Alzheimer's disease development, targeting a first candidate...

Argo's BW-20805 achieved 96% attack-rate reduction in Phase II HAE study, with 75% of patients in the 300 mg...